Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro was about as good at preventing heart attacks and strokes as its older ...

Mark Carney responds to Donald Trump raising Canada tariffs Devil's Den Murders Were 'Completely Random,' Police Say, as ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Eli Lilly and Company (NYSE:LLY) stock fell on Thursday morning after the pharmaceutical giant’s diabetes drug Mounjaro ...

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, ...

Eli Lilly's Mounjaro diabetes drug has demonstrated superior performance over Trulicity in reducing heart attack and stroke ...

Eli Lilly's Mounjaro matched Trulicity in heart outcomes and showed added benefits on A1C, weight, kidney function, and ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...